Table 7.
SLNB performance between study groups.
| Parameter | ICG (n = 24) | MB (n = 23) | ICG + MB (n = 18) | RI + MB (n = 21) | RI + ICG (n = 28) | RI + ICG + MB (n = 23) | X 2 | p |
|---|---|---|---|---|---|---|---|---|
| SLN IR | 21/24 | 19/23 | 17/18 | 19/21 | 27/28 | 23/23 | 0.042 * | |
| Mean No. of SLNs (SD) | 4.02 ± 2.3 | 2.4 ± 1.1 | 2.66 ± 1.35 | 3.2 ± 1.56 | 2.34 ± 1.2 | 3.24 ± 1.54 | −1.80 ^ | 0.074 |
| Mean metastatic SLN count | 0.29 | 0.19 | 0.25 | 0.29 | 0.32 | 0.24 | 0.38 ^ | 0.697 |
| SLN positivity rate | 33/111 (29.72) | 13/67 (19.4) | 17/66 (25.75) | 26/89 (29.21) | 31/94 (32.97) | 26/108 (24.07) | 0.47 | 0.789 |
| No. of patients with >1 SLN | 18/21 (86%) | 15/19 (79%) | 13/17 (81%) | 16/19 (88%) | 25/27 (94%) | 22/23 (97%) | 1.17 | 0.04 |
* By Fisher exact test ^ t-test.